CTLA4Ig: Effects on cellular and humoral immunity and macrophage activation

Experimental Nephrology

Volumn 5, Issue 5, 1997, Pages 370-374

  Schaub, Meike ^a   Stadlbauer, Thomas H W ^a   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN;

CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; MACROPHAGE ACTIVATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; RECEPTOR AFFINITY; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOIMMUNITY; GRAFT SURVIVAL; HUMANS; IMMUNITY, CELLULAR; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGE ACTIVATION; RECOMBINANT FUSION PROTEINS;

EID: 0030699184     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (23)

1. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 1970;169:1042-1049.
2. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 1990;11:211-216.
3. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA: Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-795.
4. Sayegh MH, Turka LA: T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction (editorial). J Am Soc Nephrol 1995;6:1143-1150.
5. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
6. Noelle RJ: CD40 and its ligand in host defense. Immunity 1996;4:415-419.
7. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792.
8. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D, et al: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11102-11105.
9. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1806.
10. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP: Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994;57:1701-1706.
11. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker BC, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
12. Perico N, Imberti O, Bontempelli M, Remuzzi G: Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. Kidney Int 1995;47:241-246.
13. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J ExpMed 1995;181:1869-1874.
14. Russell ME, Wallace AF, Hancock WW, Sayegh MH, Adams DH, Sibinga NE, Wyner LR, Karnovsky MJ: Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation 1995;59:572-578.
15. Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing JT, Willett TA, Sayegh MH: Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996;97:833-838.
16. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH: Blockade of T cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996; 93:12439-12444.
17. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB: Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995;155: 1165-1174.
18. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS: CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994;58:602-610.
19. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-718.
20. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW: CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995;155:4521-4524.
21. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-1155.
22. Nishikawa K, Linsley PS, Collins AB, Stamenkovic I, McCluskey RT, Andres G: Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 1994;24:1249-1254.
23. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994; 265:1225-1227.